WP1130 attenuates cisplatin resistance by decreasing P53 expression in non–small cell lung carcinomas

Cisplatin-based combination chemotherapy significantly improves the survival outcomes in non–small cell lung carcinomas (NSCLCs), but drug resistance commonly contributes to disease progression and relapse. Recently, accumulating evidence has indicated that deubiquitinases (DUBs) are involved in reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiang, Bao, Ying, Dong, Zhaohui, Chen, Qiuqiang, Guo, Huihui, Ziang, Charlie, Shao, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564746/
https://www.ncbi.nlm.nih.gov/pubmed/28446729
http://dx.doi.org/10.18632/oncotarget.16931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564746/
https://www.ncbi.nlm.nih.gov/pubmed/28446729
http://dx.doi.org/10.18632/oncotarget.16931

Ejemplares similares